Dolutegravir developed by GSK, is an integrase inhibitor, which prevents viral DNA from integrating into human DNA. It was approved 2013 in America. It will be used once daily as an alternative first line treatment for people who test positive for HIV in Botswana.
This drug was officially launched in Gaborone with the president participating in the event. However antiretrovirals will be kept for sicker patients.
